BDSX Relative Valuation
BDSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BDSX is overvalued; if below, it's undervalued.
Historical Valuation
Biodesix Inc (BDSX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -4.65. The fair price of Biodesix Inc (BDSX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 8.44 USD , Biodesix Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：8.44
Fair
Undervalued
-2.97
PE
1Y
3Y
5Y
Trailing
Forward
-10.13
EV/EBITDA
Biodesix Inc. (BDSX) has a current EV/EBITDA of -10.13. The 5-year average EV/EBITDA is -9.23. The thresholds are as follows: Strongly Undervalued below -24.33, Undervalued between -24.33 and -16.78, Fairly Valued between -1.68 and -16.78, Overvalued between -1.68 and 5.87, and Strongly Overvalued above 5.87. The current Forward EV/EBITDA of -10.13 falls within the Historic Trend Line -Fairly Valued range.
-4.87
EV/EBIT
Biodesix Inc. (BDSX) has a current EV/EBIT of -4.87. The 5-year average EV/EBIT is -5.97. The thresholds are as follows: Strongly Undervalued below -19.17, Undervalued between -19.17 and -12.57, Fairly Valued between 0.63 and -12.57, Overvalued between 0.63 and 7.23, and Strongly Overvalued above 7.23. The current Forward EV/EBIT of -4.87 falls within the Historic Trend Line -Fairly Valued range.
0.65
PS
Biodesix Inc. (BDSX) has a current PS of 0.65. The 5-year average PS is 3.17. The thresholds are as follows: Strongly Undervalued below -2.31, Undervalued between -2.31 and 0.43, Fairly Valued between 5.91 and 0.43, Overvalued between 5.91 and 8.65, and Strongly Overvalued above 8.65. The current Forward PS of 0.65 falls within the Historic Trend Line -Fairly Valued range.
-3.74
P/OCF
Biodesix Inc. (BDSX) has a current P/OCF of -3.74. The 5-year average P/OCF is -3.09. The thresholds are as follows: Strongly Undervalued below -9.40, Undervalued between -9.40 and -6.24, Fairly Valued between 0.07 and -6.24, Overvalued between 0.07 and 3.23, and Strongly Overvalued above 3.23. The current Forward P/OCF of -3.74 falls within the Historic Trend Line -Fairly Valued range.
-3.72
P/FCF
Biodesix Inc. (BDSX) has a current P/FCF of -3.72. The 5-year average P/FCF is -4.59. The thresholds are as follows: Strongly Undervalued below -13.21, Undervalued between -13.21 and -8.90, Fairly Valued between -0.27 and -8.90, Overvalued between -0.27 and 4.04, and Strongly Overvalued above 4.04. The current Forward P/FCF of -3.72 falls within the Historic Trend Line -Fairly Valued range.
Biodesix Inc (BDSX) has a current Price-to-Book (P/B) ratio of -37.60. Compared to its 3-year average P/B ratio of -2.77 , the current P/B ratio is approximately 1258.18% higher. Relative to its 5-year average P/B ratio of 1.20, the current P/B ratio is about -3244.64% higher. Biodesix Inc (BDSX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -40.77%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -36.66% , the current FCF yield is about -100.00% lower.
-39.45
P/B
Median3y
-2.77
Median5y
1.20
-45.02
FCF Yield
Median3y
-40.77
Median5y
-36.66
Competitors Valuation Multiple
The average P/S ratio for BDSX's competitors is 51.14, providing a benchmark for relative valuation. Biodesix Inc Corp (BDSX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 19.93%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BDSX decreased by 72.09% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 18.15M to 21.77M.
The secondary factor is the Margin Expansion, contributed -29.15%to the performance.
Overall, the performance of BDSX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Biodesix Inc (BDSX) currently overvalued or undervalued?
What is Biodesix Inc (BDSX) fair value?
How does BDSX's valuation metrics compare to the industry average?
What is the current P/B ratio for Biodesix Inc (BDSX) as of Dec 05 2025?
What is the current FCF Yield for Biodesix Inc (BDSX) as of Dec 05 2025?
What is the current Forward P/E ratio for Biodesix Inc (BDSX) as of Dec 05 2025?